Regeneron’s fund will be independently managed by former Regeneron executives Jay Markowitz and Michael Aberman, said the company, which said the primary interest of the new fund is in ...

Alabama‘s Tommy Tuberville trades more stocks than any other member of the U.S. Senate, finding himself on lists of top ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

The recent 8.5% decline in Regeneron Pharmaceuticals' share price contrasts with the broader market performance and may reflect investor concerns about near-term hurdles like the FDA's complete ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... to be a period of increased volatility, and investors who plan to add risk should be careful.

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...